Avactas’ AVA6000 Receives Orphan Drug Designation from the US FDA to Treat Soft Tissue Sarcoma
Shots:
- AVA6000 is being evaluated in an ongoing P-I study to assess the safety and PK in various cancer types, incl. soft tissue sarcoma
- AVA6000, generic version of doxorubicin that has been modified using the pre|CISION technology. It is activated in the tumor to improve the safety, efficacy, and tolerability of the drug and protect healthy tissue from exposure to CT
- The pre|CISION technology incorporates a substrate that is sensitive to cleavage by FAPα (highly upregulated in the tumor microenvironment) and generates FAPα-activated CT to prevents the drug from entering cells until the substrate is cleaved in the tumor microenvironment thus reduce the systemic exposure to the CT
Ref: Businesswire | Image: Avacta
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
